🎉 M&A multiples are live!
Check it out!

NeuroSense Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for NeuroSense Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

NeuroSense Therapeutics Overview

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.


Founded

2017

HQ

United States of America
Employees

16

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$21.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

NeuroSense Therapeutics Financials

NeuroSense Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, NeuroSense Therapeutics achieved revenue of n/a and an EBITDA of -$9.9M.

NeuroSense Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See NeuroSense Therapeutics valuation multiples based on analyst estimates

NeuroSense Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$11.2M -$9.9M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$12.3M -$11.3M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

NeuroSense Therapeutics Stock Performance

As of April 15, 2025, NeuroSense Therapeutics's stock price is $1.

NeuroSense Therapeutics has current market cap of $25.1M, and EV of $21.8M.

See NeuroSense Therapeutics trading valuation data

NeuroSense Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$21.8M $25.1M XXX XXX XXX XXX $-0.64

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

NeuroSense Therapeutics Valuation Multiples

As of April 15, 2025, NeuroSense Therapeutics has market cap of $25.1M and EV of $21.8M.

NeuroSense Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate NeuroSense Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for NeuroSense Therapeutics and 10K+ public comps

NeuroSense Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $21.8M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -2.2x XXX XXX XXX
P/E -2.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -2.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get NeuroSense Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

NeuroSense Therapeutics Valuation Multiples

NeuroSense Therapeutics's NTM/LTM revenue growth is n/a

NeuroSense Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.6M for the same period.

Over next 12 months, NeuroSense Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate NeuroSense Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for NeuroSense Therapeutics and other 10K+ public comps

NeuroSense Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -12% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

NeuroSense Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

NeuroSense Therapeutics M&A and Investment Activity

NeuroSense Therapeutics acquired  XXX companies to date.

Last acquisition by NeuroSense Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . NeuroSense Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by NeuroSense Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About NeuroSense Therapeutics

When was NeuroSense Therapeutics founded? NeuroSense Therapeutics was founded in 2017.
Where is NeuroSense Therapeutics headquartered? NeuroSense Therapeutics is headquartered in United States of America.
How many employees does NeuroSense Therapeutics have? As of today, NeuroSense Therapeutics has 16 employees.
Who is the CEO of NeuroSense Therapeutics? NeuroSense Therapeutics's CEO is Mr. Alon Ben-Noon.
Is NeuroSense Therapeutics publicy listed? Yes, NeuroSense Therapeutics is a public company listed on NAS.
What is the stock symbol of NeuroSense Therapeutics? NeuroSense Therapeutics trades under NRSN ticker.
When did NeuroSense Therapeutics go public? NeuroSense Therapeutics went public in 2021.
Who are competitors of NeuroSense Therapeutics? Similar companies to NeuroSense Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of NeuroSense Therapeutics? NeuroSense Therapeutics's current market cap is $25.1M
Is NeuroSense Therapeutics profitable? Yes, NeuroSense Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.